- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02916355
Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study (Chäs2)
Role of IL-1 in Postprandial Fatigue - The Chäschüechli 2 Study
Role of IL-1 in postprandial fatigue - The Chäschüechli 2 Study It is a randomized, single dose, placebo-controlled, double blind, cross-over, proof-of-concept study.
16 healthy young men will be included in this study. The objective of this study is to evaluate if severity of postprandial fatigue is driven by IL-1.
Since fatigue is associated with increased cytokine levels, and since fatigue in chronic inflammatory settings, such as type 2 diabetes, can be reduced by inhibition of IL-1β, postprandial fatigue might also respond to anti-inflammatory intervention with IL-1 inhibition.
The aim of the study is to investigate whether postprandial fatigue is, at least in part, driven by the IL-1 system.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Basel, Zwitserland, CH-4031 Basel
- University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Male subjects
- non-smoking
- apparently healthy
- BMI >18 and ≤28 kg/m2 or BMI >30 and ≤35 kg/m2
- Age 20-65 years
- Subject is usually eating breakfast and lunch
- Willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD) and sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner).
- Owner of a smartphone so they will be able to download and use the sleeping APP, Sleep cycle, prior to the study days.
Exclusion Criteria:
Subjects will be excluded from the study if they meet any of the following criteria:
- Night shift workers
- Subjects suffering from sleep disturbances
- Clinical signs of infection in the week before inclusion or history of infection during the last 2 months (CRP >5mg/l)
- Impaired fasting glucose (fasting plasma glucose >5.5mmol/l)
- Hematologic disease (leukocyte count < 1.5x109/l, hemoglobin <11 g/dl, platelets <100 x 103/ul)
- Kidney disease (creatinine > 1.5 mg/dl))
- Liver disease (transaminases >2x upper normal range)
- Heart disease
- Pulmonary disease
- Inflammatory disease
- History of carcinoma
- History of tuberculosis
- Alcohol consumption >40g/d
- Smoking
- Known allergy towards Kineret
- Known allergy to ingredients of the test meal
- Current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin C and E)
- Use of any investigational drug within 30 days prior to enrolment or within 5 half-lives of the investigational drug, whichever is longer
- Subject refusing or unable to give written informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Normal BMI
Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
|
Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andere namen:
subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andere namen:
|
Experimenteel: Overweight
Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
|
Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andere namen:
subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
The primary outcome is change in fatigue measured by the SSS (Stanford Sleepiness Scale) between groups treated with Anakinra vs. placebo
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Fatigue will be measured by using the SSS (Stanford Sleepiness Scale)
|
7 to 9 days (change between study day 1 and study day 2)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in postprandial glucose, insulin, C-peptide, glucagon-like Peptide (GLP)-1(active/total), GIP(active/total), PYY, IL-6, tumor necrosis factor (TNF)-alfa, sCRP and cortisol due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in heart rate due to any treatment (Anakinra vs. saline)
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Pulse watch
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in insulin due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in C-peptide due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in GLP-1(active/total) due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in GIP(active/total) due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in PYY due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in IL-6 due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in TNF-alfa due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in sCRP due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Change in cortisol due to any treatment (Anakinra vs. saline).
Tijdsspanne: 7 to 9 days (change between study day 1 and study day 2)
|
Blood sampling
|
7 to 9 days (change between study day 1 and study day 2)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Marc Y Donath, MD, University Hospital, Basel, Switzerland
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EKNZ BASEC 2016-00816
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Anakinra
-
University of AthensVoltooidCoronaire hartziekte | Ontsteking | Reumatoïde artritisGriekenland
-
Weill Medical College of Cornell UniversitySwedish Orphan BiovitrumIngetrokkenCovid19 | Mechanische beademingscomplicatie | Cytokine StormVerenigde Staten
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Ingetrokken
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Ingetrokken
-
Virginia Commonwealth UniversityAmerican Heart Association; National Center for Advancing Translational Sciences...WervingCardiale SarcoïdoseVerenigde Staten
-
National Institute of Neurological Disorders and...VoltooidAnakinra voor de behandeling van chronisch ontstoken laesies van de witte stof bij multiple scleroseMultiple scleroseVerenigde Staten
-
National Institute of Arthritis and Musculoskeletal...VoltooidZiekten van het immuunsysteem | Auto-immuun bindweefselaandoeningVerenigde Staten
-
Azienda Ospedaliero, Universitaria Ospedali RiunitiWervingTerugkerende pericarditisItalië
-
Virginia Commonwealth UniversityWerving